The Conversation (0)
MMRGlobal Inc (OTCQB:MMRF) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its anti-CD20 monoclonal antibody assets. The title for the patent is, “Antibodies and Methods for Making and Using Them” (U.S. Serial No. 11/855,943).
MMRGlobal Inc (OTCQB:MMRF) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its anti-CD20 monoclonal antibody assets. The title for the patent is, “Antibodies and Methods for Making and Using Them” (U.S. Serial No. 11/855,943).
As quoted in the press release:
This is the first U.S. patent to be granted for the Company’s anti-CD20 monoclonal antibodies, which have particular utility in fighting cancers. The anti-CD20 monoclonal antibodies are considered extremely important assets of the Company based on benefits and commercial value as demonstrated by Rituxan®, an anti-CD20 monoclonal antibody with reported sales of USD $7.285 billion in 2012, and is due to go off patent in 2015. MMR’s first anti-CD20 antibody patent was issued in Mexico in August 2012 (Mexican Patent No. 302058). Additional patent applications for the Company’s antibodies are pending in a number of other countries including Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea.
Click here to read the full MMRGlobal Inc (OTCQB:MMRF) press release.
